Skip to main content
. 2012 May 8;106(10):1626–1637. doi: 10.1038/bjc.2012.147

Table A2. Stratified analyses by blinding and intention to treat analysis.

Outcome Trials (patients) RR* (95% CI) P- value P- value for interaction test
Blinding
 Proven or probable IFI       0.52
  Blinded 4 (2284) 0.62 (0.42, 0.91) 0.01  
  Not blinded 14 (2518) 0.71 (0.52, 0.98) 0.27  
 Invasive aspergillosis       0.60
  Blinded 4 (2284) 0.47 (0.23, 0.98) 0.04  
  Not blinded 11 (22196) 0.59 (0.37, 0.95) 0.03  
 IFI-related mortality       0.88
  Blinded 3 (1686) 0.68 (0.19, 2.40) 0.54  
  Not blinded 12 (2586) 0.75 (0.49, 1.15) 0.19  
 IA-related mortality       0.60
  Blinded 2 (1084) 0.84 (0.15, 4.91) 0.85  
  Not blinded 7 (1530) 0.46 (0.12, 1.77) 0.26  
 Overall mortality       0.23
  Blinded 4 (2284) 0.92 (0.76, 1.11) 0.36  
  Not blinded 12 (2586) 1.07 (0.90, 1.28) 0.44  
         
ITT analysis
 Proven or probable IFI       0.83
  ITT 4 (1445) 0.74 (0.46, 1.17) 0.2  
  No ITT 14 (3357) 0.69 (0.44, 1.07) 0.1  
 Invasive aspergillosis       0.55
  ITT 5 (1800) 0.47 (0.27, 0.80) 0.006  
  No ITT 10 (2703) 0.58 (0.37, 0.91) 0.02  
 IFI-related mortality       0.60
  ITT 5 (1280) 0.60 (0.27, 1.33) 0.21  
  No ITT 10 (2992) 0.77 (0.49, 1.22) 0.27  
 IA-related mortality       NA
  ITT 1 (59) Not estimable NA  
  No ITT 8 (2555) 0.62 (0.23, 1.71) 0.36  
 Overall mortality       NA
  ITT 0 (0) Not estimable NA  
  No ITT 16 (4870) 1.00 (0.88, 1.13) 0.96  

Abbreviations: CI=confidence interval; IA=invasive aspergillosis; IFI=invasive fungal infection; ITT=intention-to-treat; NA=not applicable; RR=relative risk. *RR<1 represents an advantage of mould-active coverage compared with fluconazole using a random-effects model.